Accord Healthcare has received approval to market IMULDOSA®, a biosimilar of ustekinumab, which is similar to Stelara®.

SpliceBio has received IND clearance from the U.S. FDA for SB-007, allowing the start of Phase 1/2 clinical trials in Stargardt Disease patients.

Elevation Oncology broadens its pipeline with the introduction of EO-1022, a HER3 ADC aimed at treating solid tumors that express HER3.

Neurocrine Biosciences has received FDA approval for CRENESSITY™ (crinecerfont), the first of its kind therapy for both children and adults suffering from classic congenital adrenal hyperplasia.

Checkpoint Therapeutics reveals that the FDA has approved UNLOXCYT™ (cosibelimab-ipdl).

In the Phase 3 PATINA trial, Pfizer's IBRANCE® combined with standard treatments improved median progression-free survival by more than 15 months in patients.

This study was a Phase 2 trial assessing two doses of its unique selective cortisol modulator, dazucorilant, in patients diagnosed with ALS.

Galderma has obtained FDA approval in the U.S. for Nemluvio® (Nemolizumab) aimed at treating patients with moderate to severe atopic dermatitis.

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), as vital components of precision medicine, have demonstrated tremendous potential in the field of gene therapy.

Bicycle Therapeutics reveals new data on its Zelenectide Pevedotin initiative and plans to enhance development based on NECTIN4 gene amplification.

Among the many immune checkpoint inhibitors, Durvalumab (brand name Imfinzi) stands out as particularly noteworthy.

Candel Therapeutics reports that CAN-2409 met its main goal in a Phase 3 trial for prostate cancer, demonstrating a notable increase in disease-free survival.